Cargando…

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its expression is driven by sterol response element binding protein 2 (SREBP2) and follows a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cariou, Bertrand, Langhi, Cédric, Le Bras, Maëlle, Bortolotti, Murielle, Lê, Kim-Anne, Theytaz, Fanny, Le May, Cédric, Guyomarc’h-Delasalle, Béatrice, Zaïr, Yassine, Kreis, Roland, Boesch, Chris, Krempf, Michel, Tappy, Luc, Costet, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548771/
https://www.ncbi.nlm.nih.gov/pubmed/23298392
http://dx.doi.org/10.1186/1743-7075-10-4
_version_ 1782256367096037376
author Cariou, Bertrand
Langhi, Cédric
Le Bras, Maëlle
Bortolotti, Murielle
Lê, Kim-Anne
Theytaz, Fanny
Le May, Cédric
Guyomarc’h-Delasalle, Béatrice
Zaïr, Yassine
Kreis, Roland
Boesch, Chris
Krempf, Michel
Tappy, Luc
Costet, Philippe
author_facet Cariou, Bertrand
Langhi, Cédric
Le Bras, Maëlle
Bortolotti, Murielle
Lê, Kim-Anne
Theytaz, Fanny
Le May, Cédric
Guyomarc’h-Delasalle, Béatrice
Zaïr, Yassine
Kreis, Roland
Boesch, Chris
Krempf, Michel
Tappy, Luc
Costet, Philippe
author_sort Cariou, Bertrand
collection PubMed
description BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its expression is driven by sterol response element binding protein 2 (SREBP2) and follows a diurnal rhythm synchronous with cholesterol synthesis. Plasma PCSK9 is associated to LDL-C and to a lesser extent plasma triglycerides and insulin resistance. We aimed to verify the effect on plasma PCSK9 concentrations of dietary interventions that affect these parameters. METHODS: We performed nutritional interventions in young healthy male volunteers and offspring of type 2 diabetic (OffT2D) patients that are more prone to develop insulin resistance, including: i) acute post-prandial hyperlipidemic challenge (n=10), ii) 4 days of high-fat (HF) or high-fat/high-protein (HFHP) (n=10), iii) 7 (HFruc1, n=16) or 6 (HFruc2, n=9) days of hypercaloric high-fructose diets. An acute oral fat load was also performed in two patients bearing the R104C-V114A loss-of-function (LOF) PCSK9 mutation. Plasma PCSK9 concentrations were measured by ELISA. For the HFruc1 study, intrahepatocellular (IHCL) and intramyocellular lipids were measured by (1)H magnetic resonance spectroscopy. Hepatic and whole-body insulin sensitivity was assessed with a two-step hyperinsulinemic-euglycemic clamp (0.3 and 1.0 mU.kg(-1).min(-1)). FINDINGS: HF and HFHP short-term diets, as well as an acute hyperlipidemic oral load, did not significantly change PCSK9 concentrations. In addition, post-prandial plasma triglyceride excursion was not altered in two carriers of PCSK9 LOF mutation compared with non carriers. In contrast, hypercaloric 7-day HFruc1 diet increased plasma PCSK9 concentrations by 28% (p=0.05) in healthy volunteers and by 34% (p=0.001) in OffT2D patients. In another independent study, 6-day HFruc2 diet increased plasma PCSK9 levels by 93% (p<0.0001) in young healthy male volunteers. Spearman’s correlations revealed that plasma PCSK9 concentrations upon 7-day HFruc1 diet were positively associated with plasma triglycerides (r=0.54, p=0.01) and IHCL (r=0.56, p=0.001), and inversely correlated with hepatic (r=0.54, p=0.014) and whole-body (r=−0.59, p=0.0065) insulin sensitivity. CONCLUSIONS: Plasma PCSK9 concentrations vary minimally in response to a short term high-fat diet and they are not accompanied with changes in cholesterolemia upon high-fructose diet. Short-term high-fructose intake increased plasma PCSK9 levels, independent on cholesterol synthesis, suggesting a regulation independent of SREBP-2. Upon this diet, PCSK9 is associated with insulin resistance, hepatic steatosis and plasma triglycerides.
format Online
Article
Text
id pubmed-3548771
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35487712013-02-04 Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets Cariou, Bertrand Langhi, Cédric Le Bras, Maëlle Bortolotti, Murielle Lê, Kim-Anne Theytaz, Fanny Le May, Cédric Guyomarc’h-Delasalle, Béatrice Zaïr, Yassine Kreis, Roland Boesch, Chris Krempf, Michel Tappy, Luc Costet, Philippe Nutr Metab (Lond) Research BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its expression is driven by sterol response element binding protein 2 (SREBP2) and follows a diurnal rhythm synchronous with cholesterol synthesis. Plasma PCSK9 is associated to LDL-C and to a lesser extent plasma triglycerides and insulin resistance. We aimed to verify the effect on plasma PCSK9 concentrations of dietary interventions that affect these parameters. METHODS: We performed nutritional interventions in young healthy male volunteers and offspring of type 2 diabetic (OffT2D) patients that are more prone to develop insulin resistance, including: i) acute post-prandial hyperlipidemic challenge (n=10), ii) 4 days of high-fat (HF) or high-fat/high-protein (HFHP) (n=10), iii) 7 (HFruc1, n=16) or 6 (HFruc2, n=9) days of hypercaloric high-fructose diets. An acute oral fat load was also performed in two patients bearing the R104C-V114A loss-of-function (LOF) PCSK9 mutation. Plasma PCSK9 concentrations were measured by ELISA. For the HFruc1 study, intrahepatocellular (IHCL) and intramyocellular lipids were measured by (1)H magnetic resonance spectroscopy. Hepatic and whole-body insulin sensitivity was assessed with a two-step hyperinsulinemic-euglycemic clamp (0.3 and 1.0 mU.kg(-1).min(-1)). FINDINGS: HF and HFHP short-term diets, as well as an acute hyperlipidemic oral load, did not significantly change PCSK9 concentrations. In addition, post-prandial plasma triglyceride excursion was not altered in two carriers of PCSK9 LOF mutation compared with non carriers. In contrast, hypercaloric 7-day HFruc1 diet increased plasma PCSK9 concentrations by 28% (p=0.05) in healthy volunteers and by 34% (p=0.001) in OffT2D patients. In another independent study, 6-day HFruc2 diet increased plasma PCSK9 levels by 93% (p<0.0001) in young healthy male volunteers. Spearman’s correlations revealed that plasma PCSK9 concentrations upon 7-day HFruc1 diet were positively associated with plasma triglycerides (r=0.54, p=0.01) and IHCL (r=0.56, p=0.001), and inversely correlated with hepatic (r=0.54, p=0.014) and whole-body (r=−0.59, p=0.0065) insulin sensitivity. CONCLUSIONS: Plasma PCSK9 concentrations vary minimally in response to a short term high-fat diet and they are not accompanied with changes in cholesterolemia upon high-fructose diet. Short-term high-fructose intake increased plasma PCSK9 levels, independent on cholesterol synthesis, suggesting a regulation independent of SREBP-2. Upon this diet, PCSK9 is associated with insulin resistance, hepatic steatosis and plasma triglycerides. BioMed Central 2013-01-08 /pmc/articles/PMC3548771/ /pubmed/23298392 http://dx.doi.org/10.1186/1743-7075-10-4 Text en Copyright ©2013 Cariou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Cariou, Bertrand
Langhi, Cédric
Le Bras, Maëlle
Bortolotti, Murielle
Lê, Kim-Anne
Theytaz, Fanny
Le May, Cédric
Guyomarc’h-Delasalle, Béatrice
Zaïr, Yassine
Kreis, Roland
Boesch, Chris
Krempf, Michel
Tappy, Luc
Costet, Philippe
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title_full Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title_fullStr Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title_full_unstemmed Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title_short Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
title_sort plasma pcsk9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548771/
https://www.ncbi.nlm.nih.gov/pubmed/23298392
http://dx.doi.org/10.1186/1743-7075-10-4
work_keys_str_mv AT carioubertrand plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT langhicedric plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT lebrasmaelle plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT bortolottimurielle plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT lekimanne plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT theytazfanny plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT lemaycedric plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT guyomarchdelasallebeatrice plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT zairyassine plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT kreisroland plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT boeschchris plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT krempfmichel plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT tappyluc plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets
AT costetphilippe plasmapcsk9concentrationsduringanoralfatloadandaftershorttermhighfathighfathighproteinandhighfructosediets